天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Home Cart 0 Sign in  

[ CAS No. 34803-66-2 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 34803-66-2
Chemical Structure| 34803-66-2
Structure of 34803-66-2 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 34803-66-2 ]

Related Doc. of [ 34803-66-2 ]

Alternatived Products of [ 34803-66-2 ]
Product Citations

Product Citations

Li, Bowen ; Manan, Rajith Singh ; Liang, Shun-Qing , et al. DOI: PubMed ID:

Abstract: The expanding applications of nonviral genomic medicines in the lung remain restricted by delivery challenges. Here, leveraging a high-throughput platform, we synthesize and screen a combinatorial library of biodegradable ionizable lipids to build inhalable delivery vehicles for mRNA and CRISPR-Cas9 gene editors. Lead lipid nanoparticles are amenable for repeated intratracheal dosing and could achieve efficient gene editing in lung epithelium, providing avenues for gene therapy of congenital lung diseases.

Purchased from AmBeed: ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;

Product Details of [ 34803-66-2 ]

CAS No. :34803-66-2 MDL No. :MFCD00006216
Formula : C9H13N3 Boiling Point : -
Linear Structure Formula :- InChI Key :GZRKXKUVVPSREJ-UHFFFAOYSA-N
M.W : 163.22 Pubchem ID :94459
Synonyms :

Calculated chemistry of [ 34803-66-2 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 12
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.44
Num. rotatable bonds : 1
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 55.6
TPSA : 28.16 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.77 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.73
Log Po/w (XLOGP3) : 0.74
Log Po/w (WLOGP) : -0.27
Log Po/w (MLOGP) : 0.66
Log Po/w (SILICOS-IT) : 1.18
Consensus Log Po/w : 0.81

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.62
Solubility : 3.9 mg/ml ; 0.0239 mol/l
Class : Very soluble
Log S (Ali) : -0.91
Solubility : 20.1 mg/ml ; 0.123 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -2.51
Solubility : 0.502 mg/ml ; 0.00308 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.86

Safety of [ 34803-66-2 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P233-P260-P261-P264-P270-P271-P280-P301+P312-P302+P352-P304-P304+P340-P305+P351+P338-P312-P321-P330-P332+P313-P337+P313-P340-P362-P403-P403+P233-P405-P501 UN#:N/A
Hazard Statements:H302-H315-H319-H332-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 34803-66-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 34803-66-2 ]

[ 34803-66-2 ] Synthesis Path-Downstream   1~12

  • 1
  • [ 34803-66-2 ]
  • [ 17823-69-7 ]
  • (E)-2-Cyano-3-methylsulfanyl-3-(4-pyridin-2-yl-piperazin-1-yl)-acrylamide [ No CAS ]
  • 2
  • [ 50-00-0 ]
  • [ 34803-66-2 ]
  • [ 2923-66-2 ]
  • [ 861964-90-1 ]
  • 3
  • [ 401564-36-1 ]
  • [ 34803-66-2 ]
  • [ 401566-24-3 ]
  • 4
  • [ 34803-66-2 ]
  • [ 3792-04-9 ]
  • 2-[4-(2-pyridinyl)-1-piperazinyl]-N-[2-(trifluoromethyl)phenyl]acetamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
75% With sodium carbonate; In DMF (N,N-dimethyl-formamide); water; at 20℃; for 18h; [1588] A mixture of 1-pyridin-2-ylpiperazine (24 mg, 0.15 mmol, Aldrich), N-(2-trifluoromethylphenyl)-2-chloroacetamide (48 mg, 0.20 mmol, Maybridge) and sodium carbonate (50 mg) in N,N-dimethylformamide/water (2:1, 2 mL) was shaken at room temperature for 18 hours. The resulting mixture was decanted, concentrated under reduced pressure and the residue purified by preparative HPLC to provide 41 mg (75%) of the desired product. 1H NMR (500 MHz, DMSO-d6) delta2.65 (t, J=4 Hz, 4H), 3.23 (s, 2H), 3.58 (t, J=4 Hz, 4H), 6.65 (t, J=5 Hz, 1H), 6.85 (d, J=6 Hz, 1H), 7.38 (t, J=6 Hz, 1H), 7.55 (t, J=6 Hz, 1H), 7.73 (m, 2H), 8.15 (d, J=5 Hz, 1H), 8.22 (d, J=6 Hz, 1H), 9.95 (s, 1H); MS (ESI/APCI+) m/e 365 (M+H)+.
41 mg (75%) With sodium carbonate; In water; N,N-dimethyl-formamide; EXAMPLE 189 2-[4-(2-pyridinyl)-1-piperazinyl]-N-[2-(trifluoromethyl)phenyl]acetamide A mixture of 1-pyridin-2-ylpiperazine (24 mg, 0.15 mmol, Aldrich), N-(2-trifluoromethylphenyl)-2-chloroacetamide (48 mg, 0.20 mmol, Maybridge) and sodium carbonate (50 mg) in N,N-dimethylformamide/water (2:1, 2 mL) was shaken at room temperature for 18 hours. The resulting mixture was decanted, concentrated under reduced pressure and the residue purified by preparative HPLC to provide 41 mg (75%) of the desired product. 1H NMR (500 MHz, DMSO-d6) delta2.65 (t, J=4 Hz, 4H), 3.23 (s, 2H), 3.58 (t, J=4 Hz, 4H), 6.65 (t, J=5 Hz, 1H), 6.85 (d, J=6 Hz, 1H), 7.38 (t, J=6 Hz, 1H), 7.55 (t, J=6 Hz, 1H), 7.73 (m, 2H), 8.15 (d, J=5 Hz, 1H), 8.22 (d, J=6 Hz, 1H), 9.95 (s, 1H); MS (ESI/APCI+) m/e 365 (M+H)+.
  • 5
  • [ 694-05-3 ]
  • [ 91-21-4 ]
  • [ 38521-46-9 ]
  • [ 61607-68-9 ]
  • [ 34803-66-2 ]
  • C23H19BrNO2Pol [ No CAS ]
  • [ 20980-22-7 ]
  • [ 40481-13-8 ]
  • [ 6325-91-3 ]
  • [ 38026-46-9 ]
  • [ 37052-78-1 ]
  • [ 2637-37-8 ]
  • [ 64415-07-2 ]
  • [ 57658-36-3 ]
  • [ 34272-64-5 ]
  • [ 29490-19-5 ]
  • [ 24854-43-1 ]
  • [ 2252-63-3 ]
  • [ 6670-13-9 ]
  • [ 131242-36-9 ]
  • [ 35071-17-1 ]
  • [ 13906-09-7 ]
  • [ 2349-58-8 ]
  • [ 6640-24-0 ]
  • [ 51639-48-6 ]
  • C28H27N2O2Pol [ No CAS ]
  • C27H22N3O2PolS [ No CAS ]
  • C26H23N4O2PolS [ No CAS ]
  • C26H22N3O2PolS2 [ No CAS ]
  • C28H24N3O2PolS [ No CAS ]
  • C32H25N2O2PolS [ No CAS ]
  • C29H23N2O4PolS [ No CAS ]
  • C28H29N6O2PolS [ No CAS ]
  • C32H29N2O2Pol [ No CAS ]
  • C26H22N5O4PolS [ No CAS ]
  • C32H31N4O2Pol [ No CAS ]
  • C31H30N5O2Pol [ No CAS ]
  • C31H26N3O3PolS [ No CAS ]
  • C31H24N3O3PolS [ No CAS ]
  • C29H25N2O4PolS2 [ No CAS ]
  • C33H31FN3O2Pol [ No CAS ]
  • C30H26N3O5PolS [ No CAS ]
  • C30H23N4O4PolS [ No CAS ]
  • C35H32N3O2Pol [ No CAS ]
  • C33H31ClN3O2Pol [ No CAS ]
  • C38H29N2O3PolS [ No CAS ]
  • C33H24F3N2O2PolS [ No CAS ]
  • C35H34N3O3Pol [ No CAS ]
  • C38H30N3O2PolS [ No CAS ]
YieldReaction ConditionsOperation in experiment
With N-ethyl-N,N-diisopropylamine; In 1-methyl-pyrrolidin-2-one; for 20h;Combinatorial reaction / High throughput screening (HTS); Each resin from Step 3 was distributed into 24 fritted syringes (Torvig, 50 mg each, 50 mumol), for a total of 96 syringes, and was swelled in NMP (1 mL) for 30 min. The solvent was removed by filtration. Twenty-four solutions of the building blocks listed below (10 mmol each) and DIBA (3.5 mL, 20 mmol) in NMP (10 mL) were prepared. 3 mL of the 24 solutions was added to the 24 syringes for each resin from Step 3, accordingly. The suspensions were then shaken for 20 h on a Titer Plate Shaker. The reaction mixture was filtered and washed 5 times with methylene chloride (5 mL), 3 times with THF (5 mL), 3 times THF/H2O (3/1 v/v, 5 mL), and 3 times with THF (5 mL). The resins were then dried overnight under vacuum.
  • 6
  • [ 694-05-3 ]
  • [ 91-21-4 ]
  • [ 38521-46-9 ]
  • [ 61607-68-9 ]
  • [ 34803-66-2 ]
  • C22H18BrN2O2Pol [ No CAS ]
  • [ 20980-22-7 ]
  • [ 40481-13-8 ]
  • [ 6325-91-3 ]
  • [ 38026-46-9 ]
  • [ 37052-78-1 ]
  • [ 2637-37-8 ]
  • [ 64415-07-2 ]
  • [ 57658-36-3 ]
  • [ 34272-64-5 ]
  • [ 29490-19-5 ]
  • [ 24854-43-1 ]
  • [ 2252-63-3 ]
  • [ 6670-13-9 ]
  • [ 131242-36-9 ]
  • [ 35071-17-1 ]
  • [ 13906-09-7 ]
  • [ 2349-58-8 ]
  • [ 6640-24-0 ]
  • [ 51639-48-6 ]
  • C27H26N3O2Pol [ No CAS ]
  • C26H21N4O2PolS [ No CAS ]
  • C25H22N5O2PolS [ No CAS ]
  • C25H21N4O2PolS2 [ No CAS ]
  • C27H23N4O2PolS [ No CAS ]
  • C31H24N3O2PolS [ No CAS ]
  • C28H22N3O4PolS [ No CAS ]
  • C27H28N7O2PolS [ No CAS ]
  • C31H28N3O2Pol [ No CAS ]
  • C25H21N6O4PolS [ No CAS ]
  • C31H30N5O2Pol [ No CAS ]
  • C30H25N4O3PolS [ No CAS ]
  • C30H29N6O2Pol [ No CAS ]
  • C30H23N4O3PolS [ No CAS ]
  • C32H30ClN4O2Pol [ No CAS ]
  • C29H22N5O4PolS [ No CAS ]
  • C28H24N3O4PolS2 [ No CAS ]
  • C29H25N4O5PolS [ No CAS ]
  • C32H30FN4O2Pol [ No CAS ]
  • C34H31N4O2Pol [ No CAS ]
  • C34H33N4O3Pol [ No CAS ]
  • C32H23F3N3O2PolS [ No CAS ]
  • C37H28N3O3PolS [ No CAS ]
  • C37H29N4O2PolS [ No CAS ]
YieldReaction ConditionsOperation in experiment
With N-ethyl-N,N-diisopropylamine; In 1-methyl-pyrrolidin-2-one; for 20h;Combinatorial reaction / High throughput screening (HTS); Each resin from Step 3 was distributed into 24 fritted syringes (Torvig, 50 mg each, 50 mumol), for a total of 96 syringes, and was swelled in NMP (1 mL) for 30 min. The solvent was removed by filtration. Twenty-four solutions of the building blocks listed below (10 mmol each) and DIBA (3.5 mL, 20 mmol) in NMP (10 mL) were prepared. 3 mL of the 24 solutions was added to the 24 syringes for each resin from Step 3, accordingly. The suspensions were then shaken for 20 h on a Titer Plate Shaker. The reaction mixture was filtered and washed 5 times with methylene chloride (5 mL), 3 times with THF (5 mL), 3 times THF/H2O (3/1 v/v, 5 mL), and 3 times with THF (5 mL). The resins were then dried overnight under vacuum.
  • 7
  • [ 694-05-3 ]
  • [ 91-21-4 ]
  • [ 38521-46-9 ]
  • [ 61607-68-9 ]
  • [ 34803-66-2 ]
  • C29H23BrNO2Pol [ No CAS ]
  • [ 20980-22-7 ]
  • [ 40481-13-8 ]
  • [ 6325-91-3 ]
  • [ 38026-46-9 ]
  • [ 37052-78-1 ]
  • [ 2637-37-8 ]
  • [ 64415-07-2 ]
  • [ 57658-36-3 ]
  • [ 34272-64-5 ]
  • [ 29490-19-5 ]
  • [ 24854-43-1 ]
  • [ 2252-63-3 ]
  • [ 6670-13-9 ]
  • [ 131242-36-9 ]
  • [ 35071-17-1 ]
  • [ 13906-09-7 ]
  • [ 2349-58-8 ]
  • [ 6640-24-0 ]
  • [ 51639-48-6 ]
  • C33H26N3O2PolS [ No CAS ]
  • C34H31N2O2Pol [ No CAS ]
  • C32H27N4O2PolS [ No CAS ]
  • C34H28N3O2PolS [ No CAS ]
  • C32H26N3O2PolS2 [ No CAS ]
  • C38H29N2O2PolS [ No CAS ]
  • C35H27N2O4PolS [ No CAS ]
  • C38H33N2O2Pol [ No CAS ]
  • C34H33N6O2PolS [ No CAS ]
  • C32H26N5O4PolS [ No CAS ]
  • C37H28N3O3PolS [ No CAS ]
  • C38H35N4O2Pol [ No CAS ]
  • C37H34N5O2Pol [ No CAS ]
  • C37H30N3O3PolS [ No CAS ]
  • C35H29N2O4PolS2 [ No CAS ]
  • C36H27N4O4PolS [ No CAS ]
  • C36H30N3O5PolS [ No CAS ]
  • C41H36N3O2Pol [ No CAS ]
  • C39H35FN3O2Pol [ No CAS ]
  • C39H35ClN3O2Pol [ No CAS ]
  • C39H28F3N2O2PolS [ No CAS ]
  • C44H33N2O3PolS [ No CAS ]
  • C41H38N3O3Pol [ No CAS ]
  • C44H34N3O2PolS [ No CAS ]
YieldReaction ConditionsOperation in experiment
With N-ethyl-N,N-diisopropylamine; In 1-methyl-pyrrolidin-2-one; for 20h;Combinatorial reaction / High throughput screening (HTS); Each resin from Step 3 was distributed into 24 fritted syringes (Torvig, 50 mg each, 50 mumol), for a total of 96 syringes, and was swelled in NMP (1 mL) for 30 min. The solvent was removed by filtration. Twenty-four solutions of the building blocks listed below (10 mmol each) and DIBA (3.5 mL, 20 mmol) in NMP (10 mL) were prepared. 3 mL of the 24 solutions was added to the 24 syringes for each resin from Step 3, accordingly. The suspensions were then shaken for 20 h on a Titer Plate Shaker. The reaction mixture was filtered and washed 5 times with methylene chloride (5 mL), 3 times with THF (5 mL), 3 times THF/H2O (3/1 v/v, 5 mL), and 3 times with THF (5 mL). The resins were then dried overnight under vacuum.
  • 8
  • [ 694-05-3 ]
  • [ 91-21-4 ]
  • [ 38521-46-9 ]
  • [ 61607-68-9 ]
  • [ 34803-66-2 ]
  • C29H23ClNO2Pol [ No CAS ]
  • [ 20980-22-7 ]
  • [ 40481-13-8 ]
  • [ 6325-91-3 ]
  • [ 38026-46-9 ]
  • [ 37052-78-1 ]
  • [ 2637-37-8 ]
  • [ 64415-07-2 ]
  • [ 57658-36-3 ]
  • [ 34272-64-5 ]
  • [ 29490-19-5 ]
  • [ 24854-43-1 ]
  • [ 2252-63-3 ]
  • [ 6670-13-9 ]
  • [ 131242-36-9 ]
  • [ 35071-17-1 ]
  • [ 13906-09-7 ]
  • [ 2349-58-8 ]
  • [ 6640-24-0 ]
  • [ 51639-48-6 ]
  • C33H26N3O2PolS [ No CAS ]
  • C34H31N2O2Pol [ No CAS ]
  • C32H27N4O2PolS [ No CAS ]
  • C34H28N3O2PolS [ No CAS ]
  • C32H26N3O2PolS2 [ No CAS ]
  • C38H29N2O2PolS [ No CAS ]
  • C35H27N2O4PolS [ No CAS ]
  • C34H33N6O2PolS [ No CAS ]
  • C38H33N2O2Pol [ No CAS ]
  • C32H26N5O4PolS [ No CAS ]
  • C37H30N3O3PolS [ No CAS ]
  • C37H34N5O2Pol [ No CAS ]
  • C38H35N4O2Pol [ No CAS ]
  • C37H28N3O3PolS [ No CAS ]
  • C35H29N2O4PolS2 [ No CAS ]
  • C36H27N4O4PolS [ No CAS ]
  • C39H35FN3O2Pol [ No CAS ]
  • C36H30N3O5PolS [ No CAS ]
  • C39H35ClN3O2Pol [ No CAS ]
  • C41H36N3O2Pol [ No CAS ]
  • C39H28F3N2O2PolS [ No CAS ]
  • C44H33N2O3PolS [ No CAS ]
  • C41H38N3O3Pol [ No CAS ]
  • C44H34N3O2PolS [ No CAS ]
YieldReaction ConditionsOperation in experiment
With N-ethyl-N,N-diisopropylamine; In 1-methyl-pyrrolidin-2-one; for 20h;Combinatorial reaction / High throughput screening (HTS); Each resin from Step 3 was distributed into 24 fritted syringes (Torvig, 50 mg each, 50 mumol), for a total of 96 syringes, and was swelled in NMP (1 mL) for 30 min. The solvent was removed by filtration. Twenty-four solutions of the building blocks listed below (10 mmol each) and DIBA (3.5 mL, 20 mmol) in NMP (10 mL) were prepared. 3 mL of the 24 solutions was added to the 24 syringes for each resin from Step 3, accordingly. The suspensions were then shaken for 20 h on a Titer Plate Shaker. The reaction mixture was filtered and washed 5 times with methylene chloride (5 mL), 3 times with THF (5 mL), 3 times THF/H2O (3/1 v/v, 5 mL), and 3 times with THF (5 mL). The resins were then dried overnight under vacuum.
  • 9
  • [ 34803-66-2 ]
  • [ 129722-34-5 ]
  • 7-(4-(4-(pyridin-2-yl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one [ No CAS ]
YieldReaction ConditionsOperation in experiment
60.8% With potassium carbonate; In acetonitrile; at 60 - 65℃;Inert atmosphere; General procedure: To a mixture of the corresponding secondary amines 4a?4k(0.6 mmol), anhydrous K2CO3 (89.7 mg, 0.65 mmol) in anhydrousCH3CN (7 mL) were added the appropriate intermediates 10?13(0.5 mmol). The reaction mixture was warmed to 60?65 C andstirred for 6?10 h under an argon atmosphere. After complete reaction,the solvent was evaporated under reduced pressure. The residuewas dissolved in water (30 mL) and the mixture was extractedwith dichloromethane (20 mL 3). The combined organic phaseswere washed with saturated aqueous sodium chloride (30 mL),dried over sodium sulfate, and filtered. The solvent was evaporatedto dryness under reduced pressure. The residue was purified on asilica gel chromatography using mixtures of dichloromethane/acetone(30:1) as eluent to afford the corresponding 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives TM1?TM31.
  • 10
  • [ 34803-66-2 ]
  • [ 546-43-0 ]
  • (3R,3aR,5S,8aR,9aR)-5,8a-dimethyl-3-[4-(2-pyridyl)piperazin-1-yl]methyl}-3a,5,6,7,8,8a,9,9a-octahydronaphtho[2,3-b]furan-2(3H)-one [ No CAS ]
YieldReaction ConditionsOperation in experiment
81% In methanol; at 20℃; for 12h; General procedure: Lactone (1 mmol) in MeOH (5 mL) wasstirred, treated with a solution of piperazine (1 mmol) in MeOH (2 mL), and left at room temperature. The course of thereaction was monitored by TLC. If the product did not precipitate, the solvent was evaporated in vacuo after the reaction wascomplete. The residue was recrystallized from a suitable solvent (usually C6H6-hexane mixtures). Compounds 5a-e, 6a-d,and 7a,d,e were prepared by this method.
  • 11
  • [ 19745-07-4 ]
  • [ 34803-66-2 ]
  • 2-chloro-5-(4-(pyridin-2-yl)piperazin-1-yl)pyrazine [ No CAS ]
YieldReaction ConditionsOperation in experiment
55% With caesium carbonate; In N,N-dimethyl-formamide; at 55℃; for 17h; l-(Pyridin-2-yl)piperazine (1.64 g, 1.53 ml, 10.1 mmol), <strong>[19745-07-4]2,5-dichloropyrazine</strong> (1.5 g, 10.1 mmol) and CS2CO3 (5.25 g, 16.1 mmol) were dissolved in DMF (40 ml). The solution was stirred 17 h at 55 C. The solution was diluted with H20, then extracted with DCM (4 x) The combined organic layers were washed with brine, dried over MgS04, filtered and con centrated under vacuum. The crude material was purified by flash chromatography (DCM to DCM/0.6%MeOH) to yield 2-chloro-5-(4-(pyridin-2-yl)piperazin-l-yl)pyrazine (1.57 g, 55%). Light yellow solid. LC-MS: m/z = 276.l.[M+H]+.
  • 12
  • [ 34803-66-2 ]
  • [ 51997-51-4 ]
  • 1-((9H-carbazol-4-yl)oxy)-3-(4-(pyridin-2-yl)piperazin-1-yl)propan-2-ol [ No CAS ]
YieldReaction ConditionsOperation in experiment
81% In isopropyl alcohol; for 5h;Inert atmosphere; Reflux; General procedure: Corresponding 2-(aryloxymethyl)oxiranes (5 mmol, 1 equiv) and amines (7.5 mmol, 1.5 equiv) were dissolved in 30 mL i-PrOH. The reaction was purged with argon 3 times and stirred at reflux for 5 h, andthen the mixture was cooled to room temperature and added AcOEt.After washing with brine 3 times, the organic layer was dried overanhydrous Na2SO4, filtered, and evaporated in vacuo. Purification ofthe crude residue by column chromatography on silica gel yielded target compounds.
Recommend Products
Same Skeleton Products

Technical Information

Historical Records

Related Parent Nucleus of
[ 34803-66-2 ]

Pyridines

Chemical Structure| 74764-17-3

[ 74764-17-3 ]

N1-(Pyridin-2-yl)ethane-1,2-diamine

Similarity: 0.91

Chemical Structure| 5028-17-1

[ 5028-17-1 ]

2-(4-Methylpiperazin-1-yl)pyridin-3-amine

Similarity: 0.87

Chemical Structure| 885277-30-5

[ 885277-30-5 ]

1-(4-Chloropyridin-2-yl)piperazine

Similarity: 0.82

Chemical Structure| 144465-94-1

[ 144465-94-1 ]

1-(Pyridin-2-yl)piperidin-4-amine

Similarity: 0.81

Chemical Structure| 345310-98-7

[ 345310-98-7 ]

1-(Pyridin-2-yl)piperazin-2-one

Similarity: 0.79

Piperazines

Chemical Structure| 5028-17-1

[ 5028-17-1 ]

2-(4-Methylpiperazin-1-yl)pyridin-3-amine

Similarity: 0.87

Chemical Structure| 885277-30-5

[ 885277-30-5 ]

1-(4-Chloropyridin-2-yl)piperazine

Similarity: 0.82

Chemical Structure| 345310-98-7

[ 345310-98-7 ]

1-(Pyridin-2-yl)piperazin-2-one

Similarity: 0.79

Chemical Structure| 4774-24-7

[ 4774-24-7 ]

2-(Piperazin-1-yl)quinoline

Similarity: 0.76

Chemical Structure| 1057682-05-9

[ 1057682-05-9 ]

(R)-6-(3-Methylpiperazin-1-yl)nicotinonitrile

Similarity: 0.74

; ;